EBOS director's performance rights lapse, reducing holding

Matthew Musico, chief executive of EBOS Medical Technology and a director of EBOS Group Limited, experienced a lapse of 15,828 performance rights on September 4, 2025. These rights were initially granted during his employment and lapsed in accordance with their terms of issue.

Prior to this change, Musico held 33,687 performance rights. Following the lapse, his direct holding of performance rights now stands at 17,859. The notification, an Appendix 3Y filing, updates a previous notice dated January 3, 2025.

The change in director's interest exclusively involved the lapse of performance rights, with no acquisition of new securities reported. The nature of this change is explicitly stated as the "Lapse of performance rights in accordance with their terms of issue."